The presence of perineural invasion in a prostate biopsy has important implications for active surveillance.
New findings challenge recommendations from the European Association of Urology.
Increases in waist-to-hip ratio, body mass index, waist circumference, and total body fat percentage were associated with increases in the risk of prostate cancer death.
Some patients with a negative mpMRI while on prostate cancer active surveillance may be able to defer biopsy, according to investigators.
Active surveillance appears to be a safe treatment option for low- and very low-risk prostate cancer, regardless of race, according to investigators.
Following the approval of cabazitaxel in 2010, there are now an unprecedented number of life-prolonging therapies for men with metastatic disease.
Study characterized patient-reported delays in care of prostate cancer and bladder cancer at the national level.
Grade group 1 prostate cancers declined as a proportion of all prostate cancers.
A novel life expectancy calculator could allow for more personalized management of men with prostate cancer.
Of more than 100 studies used to support drug approvals, none reported information on the gender of participants.
Patients with certain cancers have an increased risk of cancer-specific mortality that persists for 30 to 35 years after diagnosis.
The use of proton beam therapy (PBT) increased between 2004 and 2018, particularly for cancers in which the effectiveness of PBT is still under investigation.
Orteronel is likely not effective when compared with recently approved agents, according to researchers.
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
There was no significant benefit with long-term ADT, but researchers said there was a “clinically relevant” benefit in patients with high-risk disease.
Between March 2020 and March 2021, the estimated number of missed prostate cancer diagnoses ranged from 97 cases to 573 cases.
Immune checkpoint inhibitors were more effective than taxanes in patients with a high tumor mutational burden.
Study confirms the care gap in bone health management and fracture prevention among older men with prostate cancer receiving androgen deprivation therapy.
An analysis revealed a link between treatment with androgen deprivation therapy and new diagnoses of incident depression and anxiety in men with prostate cancer.
Patients with perineural invasion had a 4-fold higher risk of biochemical recurrence.